<- Go Home
Cue Biopharma, Inc.
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company’s lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company’s lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Market Cap
$178.8M
Volume
209.8K
Cash and Equivalents
N/A
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$37.3M
Profit Margin
99.15%
52 Week High
$45.50
52 Week Low
$4.97
Dividend
N/A
Price / Book Value
55.71
Price / Earnings
-0.68
Price / Tangible Book Value
55.71
Enterprise Value
$164.4M
Enterprise Value / EBITDA
-1.73
Operating Income
N/A
Return on Equity
1603.48%
Return on Assets
-172.66
Cash and Short Term Investments
N/A
Debt
N/A
Equity
N/A
Revenue
N/A
Unlevered FCF
-$33.3M
Sector
Biotechnology
Category
N/A